Decrease elevated total cholesterol (total-C), LDL-C & Triglycerides (TG) & increase HDL-C in adults with primary hypercholesterolemia (heterozygous familial & nonfamilial) or mixed dyslipidemia (Fredrickson types IIa & IIb). Decrease Apo B, non-HDL-C, VLDL-C, VLDL-TG, LDL-C/HDL-C, total-C/HDL, nonHDL-C/HDL-C & Apo B/Apo A-I in adults. Adults with isolated hypertriglyceridemia (Fredrickson type IV hyperlipidemia). Decreases total-C % LDL-C in adults with HoFH as adjunct to other lipid-lowering treatments (eg, LDL apheresis) or alone if such treatments are unavailable. Slows progression of atherosclerosis in adults as part of treatment strategy to decrease total-C & LDL-C to target levels. Decrease total-C, LDL-C & Apo B levels in children & adolescents 10-17 years (boys Tanner stage >II, & girls at least 1 year post-menarche) with heterozygous familial hypercholesterolemia if after adequate trial of diet therapy the following findings are present: LDL-C >90 mg/dL, or LDL-C >160 mg/dL & there is +ve family history of premature CV disease or >2 other CV risk factors are present in the patient. Decrease risk of stroke, MI & arterial revascularization procedures in individuals without clinically evident CHD but with increased risk of CV disease based on age (>50 year in men & >65 year women), hsCRP >2 mg/L, & presence of at least 1 additional CV disease risk factor eg, HTN, low HDL-C, smoking, or family history of premature CHD.

This is not a substitute for consulting your doctor. Seek professional advice if you are experiencing any illness or symptoms.

May be taken with or without food.